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Abstract
The conditions favouring effective specific cytotoxic T lymphocyte (CTL) priming have been
exploited to set up a simple and reproducible method to Induce a primary CTL response In vitro.
We report that cultured monocytes, as well as activated T cells, pulsed with exogenous HLA-A2
binding immunogenic peptides, can induce primary peptlde-specific CTL responses In vitro in a
Th-lndependent manner. Primary viral peptide-induced CTL were HLA-A2 restricted, and recognized
both peptlde-pulsed target cells and targets infected with recomblnant vaccinia virus expressing
viral endogenous antigens. In addition, both cultured monocytes and activated T cells primed
peptide-speciflc CD8+ T cells depleted from the CD45RO+ memory cell fraction. The efficiency of
CTL priming by monocytes was dependent upon the strong up-regulation of class I, adhesion and
co-stimulatory molecules occurring spontaneously upon In vitro culture. The Inability of
unseparated peripheral blood mononuclear cells to mount a peptlde-speclflc CTL response could
be reverted by direct co-stimulation of responding CD8+ T cells by soluble B7.1 or a stimulatory
anti-CD28 antibody, that allowed a specific response to take place. Although co-stimulation via the
B7-CD28 interaction appeared sufficient to trigger CTL responses, it was not essential for CTL
priming, since neither anti-B7.1 mAb nor soluble CTLA-4 Inhibited Induction of primary CTL
response. This new method for Induction of specific CD8+ T cell response In vitro may be
exploited in adoptive Immunotherapy in cancer or In HIV-lnfected patients.
Introduction
Recent advances in understanding the interaction between
naturally processed peptides and MHC molecules allow the
identification of the likely immunogenic peptides in a protein
sequence on the basis of the presence of specific anchors
(1). Peptides binding to MHC class I molecules, which are
in general 9-10 residues long, usually contain within their
sequence two anchor residues interacting with corresponding
binding pockets in the MHC molecule (2-4). The binding can
be measured in vitro by demonstrating the capacity of the
synthetic peptide to assist the folding of a particular class I
molecule (1,5-7). Definition of specific MHC motifs allows us
to predict those peptides derived from viral or tumor antigens,
potentially immunogenic for CTL.
Synthetic peptides have been used not only to identify the
epitopes of a protein recognized by specific cytotoxic T
lymphocytes (CTL), but also as vaccines to induce protective
CTL in mouse (8-20). Moreover, peptides conjugated to either
a helper epitope or lipid have been used to induce protective
CTL responses (21,22). Alternatively, with regard to adoptive
immunotherapy, i.e. in cancer patients or in severe immuno-
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compromised HIV carriers, one of the two following
approaches may be considered: either the in vivo transfer of
in wrro-primed, well characterized peptide-specific CTL, or
peptide vaccination using well characterized peptides, that
could be delivered on professional APC.
However, it would be desirable to set up a simple and
reproducible method to induce primary antigen-specific CTL
response in vitro. Indeed, such an approach may be essential
to identify not only immunogenic peptides, but also the
most appropriate professional APC capable of triggering CTL
precursors. The prerequisite for such APC is to present a
high density of peptide-MHC molecule complexes (signal 1)
and to simultaneously deliver the co-stimulatory signals (signal
2) required for T cell activation, which has been defined as
B7.1 or B7.2 interacting with CD28/CTLA-4 on T cells (23-26).
The strategies to induce primary CTL responses in vitro
and the conditions that determine effective CTL priming as
well as unfavourable conditions are reported herein.
Methods
Identification of HLA-A2.1 binding peptides
Peptides of HIVgp120 and hepatitis B envelope antigen
(HBenvAg; subtype ADW2) carrying HLA-A2.1 motif (1) were
synthesized by the solid-phase method on an automated
multiple peptide synthesizer (AMS 422; Abimed, Langenfeld,
Germany) using Fmoc chemistry. The purity of peptides was
determined by reverse-phase HPLC. Peptides were diluted
to a concentration of 2 mg/ml and stored at -20°C. The
peptides were screened for their ability to stabilize HLA-A2.1
molecules on the surface of transporter defective mutant T2
cells (27,28). T2 cells were cultured in RPMI 1640 (HyClone,
Logan, UT) supplemented with 10% FCS (HyClone), 2 mM L-
glutamine, 1% sodium pyruvate, 100 U/ml penicillin, 100 jig/
ml streptomycin and 2 jig/ml fungizone (Flow, Irvine, UK)
(complete medium). T2 cells were washed twice and resus-
pended in either serum-free medium in the presence of
10 \iglm\ human f^microglobulin (fern) (Sigma, St Louis, MO)
or complete medium and incubated in 96-well flat-bottom
plates in the presence or absence of different concentrations
of peptide overnight at 37°C, 5% CO2. Cells were washed
and stained with an anti-HLA-A2.1 mAb (lgG2a, BB7.2; ATCC,
Rockville, MD) for 30 min at 4°C followed by FITC-F(ab)'2
goat anti-mouse Ig (GAM). Cells were washed twice and
analysed using a FACScan (Becton Dickinson, Mountain
View, CA).
Peptides showing high levels of stabilization of class I on
T2 cells were studied for their ability to bind HLA-A2.1 by a
direct binding assay, that is based on serologic detection of
the conformational change of HLA class I a-chains induced
by binding to specific peptides in the presence of fem,
as described (29). Briefly, Epstein-Barr virus transformed-B
(EBV-B) cells were lysed in Tris-HCI, pH 7.5, containing
0.5% NP-40 and protease inhibitors, and the lysates were
denaturated by alkaline dissociation. The unfolded a-chain
was separated from fern and peptides by gel filtration. The
fractions containing the first major protein peak were pooled
and incubated with test peptides and excess p2m for 16 h at
25CC. The increase in folded a-chain activity induced by
peptide binding was quantitated by a specific radioimmuno-
assay involving a rabbit anti-HLA class I serum and
125l-labelled purified HLA-A2.1 molecules.
Purification of CD8* T cells
Human peripheral blood mononuclear cells (PBMC) were
isolated from HLA-A2+ healthy donors on Lymphoprep cush-
ions (LSM; Organon Teknika, Durham, NC). Donors were
negative for HBV and HIV serological markers. PBMC were
then washed in serum-free medium and allowed to adhere to
24-well plates (Falcon) in RPMI-1% human AB serum. After
90 min at 37°C the non-adherent cells were removed and
used for cell purification as described (30). Briefly, CD8+ T
cells were isolated by immunomagnetic separation with anti-
CD8 mAb attached to Dynabeads (Dynal, Oslo, Norway).
Positively selected cells were detached from magnetic beads
by incubation with Detachabead (Dynal) according to the
manufacturer's instructions. After the treatment, purified CD8+
and CD8"T cells were >98% CD8+ and < 1 % CD8~ respect-
ively. In some experiments, a CD45RA+CD45RO~ population
was isolated from purified CD8+ T cells by depletion of
CD45R0"1" cells with anti-CD45RO+ mAb attached to mag-
netic beads.
In vitro priming with peptide
PBMC (4-5X106) were incubated in RPMI-1% human AB
serum in culture 24-well culture plates (Falcon) for 90 min at
37°C, 5% CO2; the non-adherent cells were removed, and
the adherent fraction was pulsed with different concentrations
of peptide in serum-free medium for 4 h and used as APC.
Adherent cells were then incubated with 1.5X106 responding
purified CD8+ T cells in the presence or absence of different
concentrations of an anti-B7.1 mAb (31) or a fusion protein
between human CTLA-4 and human lgG1 (huCTLA-4-
hulgGI) (32). In some experiments we used as APC either
an irradiated (3000 rad) autologous T cell clone, or irradiated
(3000 rad) autologous PBMC or irradiated (13,000 rad) autol-
ogous EBV-B cells. In some experiments, either a fusion
protein between human B7.1 and IgM (huB7.1-lgM) or an
anti-CD28 mAb were added to cultures in which irradiated
PBMC were used as APC.
In all cases after 2 days of culture, 50 U/ml rlL-2 (Proleukin;
Eurocetus, Emeryville, CA) was added and after a further 5
days, CD8+ T cells were re-stimulated with irradiated autolog-
ous phytohaemagluttinin (PHA)-T cell blasts pulsed with 10
ng/ml peptide. After a second administration of IL-2, viable
CD8+ T cells from each culture were tested for specific
cytotoxicity on day 7 from the secondary stimulation.
Generation of CTL clones
T cell clones were isolated and maintained as previously
described (33). Briefly, primary peptide-specific CTL were
cloned by limiting dilution at 0.3 cells/well onto 96-well U-
bottom plates in the presence of 0.5 ng/ml PHA-P (Wellcome
Beckenham, UK), 50 U/ml rlL-2 and irradiated allogeneic
feeder cells. After 2-3 weeks, cell growth was detected using
an inverted microscope and growing cultures were tested for
their capacity to mount a specific cytotoxic response to
peptide-pulsed 51Cr-labelled target cells. Peptide-specific
CTL clones were then expanded in rll-2-containing medium
and maintained in culture with 2 week cycles of re-stimulation
with PHA plus allogeneic APC.
CTL assay
Cytotoxicity of CD8+ T cells, primed with peptide-pulsed APC,
was tested in a 6 h 51Cr-release assay. T cells were used as
effector cells at an E:T ratio ranging from 50:1 to 20:1. Effector
cells were incubated in triplicate in U-bottom microtitre wells
(Falcon), containing 5X103 51Cr-labelled homozygous HLA-
A2.1+ EBV-B cells. Target cells were labelled with 100 nCi of
Na51Cr (Amersham, Buckinghamshire, UK) for 2 h and then
pulsed with 10 ng/ml peptide for 1 h at 4°C or left unpulsed. In
some experiments anti-HLA-A2 mAb or an anti-HLA-B27 mAb
were added at the initiation of the assay.
In some experiments, EBV-B cells infected with recombinant
vaccinia virus (rW) expressing gp160 (VPE16) or with VSC8
as control were used as target cells. The rW were kindly
donated by Andrea De Maria (University of Genova, Italy).
EBV-B cells (1.5X106) were incubated with 1 p.f.u./ixiO6
cells of the different preparations of rW at 4°C for 10 min,
washed and resuspended in 5 ml complete medium and
incubated at 37°C, 5% CO2, for 12 h before being used as
target cells.
F7\CS analysis
The following purified specific mAb were used: anti-CD3
(lgG1, TR66), anti-CD4 (IgGI, 6D10), anti-HLA-A2.1 (lgG2a,
BB7.2), anti-HLA-DR (lgG2a, L243), anti-HLA-DQ (lgG2a,
SPVL3), anti-HLA-DP (lgG1, B7.21) and anti-B7.1 (lgG2a,
B7.24); anti-CD28 (IgM, CK248) was kindly donated by Sandro
Poggi (1ST National Institute for Cancer Research, Genova,
Italy) (34); anti-HLA-B27 (lgG1, MEI) was kindly donated by
Rossella Sorrentino (Department of Experimental Medicine,
University of L'Aquila, Italy); anti-CD19 (IgGI, J4.119), anti-
CD13 (IgGI, SJ.1D1), anti-CD14 (lgG2a, RMO52), anti-
CD45RA (IgGI, ALB11), anti-CD45RO (lgG2A, UCHL1), anti-
CD1a (IgGI, BL6), anti-CD1b (lgG2a, 4.A7.6) and anti-CD1c
(IgGI, L161) were purchased from Immunotech (Marseille,
France); anti-CD11a (LFA-1, IgG, TEC-NK2) was purchased
from TechnoGenetics (Milan, Italy); anti-HLA-ABC (lgG2a,
W6.32) and anti-CD54 (ICAM-1, IgGI, 15.2) were purchased
from Sera-Lab (Crawley Down, UK); and FITC-F(ab)'2 GAM
was purchased from TechnoGenetics.
Cells were labelled with mAb on ice for 30 min, washed
four times, incubated for 30 min on ice with FITC-F(ab)'2
GAM Ig, washed again and immediately analysed on FACScan
flow cytometer (Becton Dickinson) equipped with a 15 mW air-
cooled 488 nm argon-ion laser. The cytometer was calibrated
using three different types of CaliBRITE (Becton Dickinson)
beads of -6.6 |im in diameter. Gating was performed using
a combination of forward and orthogonal light scatter (linear
amplification). Propidium iodide was used to exclude dead
cells. Data of 10,000 events was acquired and stored in list
mode using the FACScan research software. The Lysys 111.1
program was used for analysis of data.
Soluble human B7.1-lgM molecule
The generation and characterization of the soluble huB7.1-
IgM will be described in detail elsewhere (P. Dellabona
and G. Casorati, manuscript in preparation). Briefly, total
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cytoplasmic RNA extracted from an EBV-transformed cell
line was reverse transcribed into cDNA, and the sequence
encoding for the extracellular domains of the human B7.1
molecule was amplified by PCR using the following oligonucle-
otide: 5'-CCTGAGCTCCTGAAGCCATGGGCCACACACGG-
3' and 5'-TCTGACTTACCATCAGGAAAATGCTCTTGCTT-3'
(underlined is a consensus splicing donor site). The PCR was
run with the following conditions: 20 s at 94°C, 30 s at 60°C
and 30 s at 72°C for 20 cycles. The amplified product was
cloned blunt ended into the pBluescript vector, sequenced
to rule out PCR errors and subcloned into the Ssfl-SaA
digested pCD4-hCu expression vector. The huB7.1-lgM was
transfected by protoplast fusion into the mouse plasmocytoma
cell line J558L as described (35) and the clones secreting
the highest amount of proteins (3-5 |ig/ml) were selected for
expansion.
The approximate size of the B7.1-lgM was determined
on an SDS-PAGE gel. Briefly, the B7.1-lgM protein was
precipitated from culture supernatant using the anti-B7.1 mAb
B7.24 (31) and Protein G (Pharmacia, Uppsala, Sweden),
run on an SDS-PAGE both in reducing and non-reducing
conditions, and blotted on a nitrocellulose filter. The filter
was decorated with alkaline phosphatase-labelled GAM Ig
(Southern Biotechnology, Birmingham, AL) followed by ECL
(Amersham). Under reducing conditions, the B7.1-lgM
migrated as a single molecular species of -130 kDa, while
under non-reducing condition it migrated with an apparent
Mr of 700, consistent with the pentameric structure determined
by the IgM Fc portion. To prepare the B7.1-lgM containing
supernatant, the J558L clone secreting it was grown in
standard RPMI medium (Hyclone) containing 7% FCS in a
Miniperm fermenter (Haereus, Germany). We determined
as 1:10 the optimal dilution of B7.1-lgM containing super-
natant giving the highest proliferative response on purified
human CD4+ CD45RO T cells, stimulated with a sub-
optimal dose of anti-CD3 mAb. The proliferative response
was measured by [3H]thymidine incorporation in a stand-
ard 72 h assay, and for each B7.1-lgM dilution was 1:10 =
47,000 C.p.m., 1:20 = 40,000 c.p.m., 1:40 = 38,000 c.p.m.,
1:80 = 32,000 c.p.m. and 1:100 = 25,000 c.p.m. A spare
culture supernatant used as a control gave the same back-
ground incorporation of 2000 c.p.m. at all dilutions tested.
Results
Identification of HLA-A2 binding peptides
T cell determinants to be used for the induction of CTL
responses in vitro were identified using the known HLA-A2
binding motif (5,6). Forty-eight nonamers carrying the A2
motif were screened for their capacity to stabilize HLA-A2
molecules on the surface of the transporter defective mutant
T2 cells essentially as described (36). A peptide of HIVgp120
(121-129; KLTPLCVSL) and a peptide of HBenvAg (335-
343; WLSLLVPFV), that showed high levels of binding, were
selected for functional experiments, according to our prelimin-
ary experiments demonstrating that CTL specific for those
peptides efficiently cross-reacted on endogenous antigen
presenting target cells. As shown in Rg. 1, these peptides
can stabilize cell surface A2 molecules on T2 cells and can
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Fig. 1. Identification of HLA-A2 binding peptides. (a) Stabilization of surface HLA-A2 molecules in T2 cells by HIVgp12O(121-129) and by
HBenvAg(335-343) peptides as detected by surface staining with anti-HLA-A2 antibody, (b) Effect of peptide and fem on refolding of HLA-
A2 a-chains isolated from the HLA homozygous cell line, JY (A0201, B7, X), as detected by a specific radioimmunoassay. One unit of activity
detected by the radioimmunoassay is defined as the amount of test sample that induces a 50% inhibition of the specific binding involved in
the assay system. The results are presented as a activity/ml of test sample. Bars indicate a activity above the control (a-chain
- Bom only). Flu-MP58-66 and HIV-RT476-484 represent positive controls, while HBV120-130,130-140 and 125-133 represent negative controls.
assist the refolding of isolated A2 a chains in the presence
of fern.
Characterization of APC for in vitro priming
Initial attempts to induce primary CTL responses by directly
adding the HLA-A2 binding peptides to PBMC of HLA A2+
donors were unsuccessful (data not shown). We reasoned
that the failure to induce a specific response might be due
either to insufficient number of sites available on APC or to
inappropriate presentation, i.e. presentation on non-profes-
sional APC (26) or on the responding T cells themselves (37).
We therefore asked whether selective display of the peptide
on professional APC may favour stimulatory interactions and
lead to CTL priming.
We tested different sources of APC: PBMC, EBV-B cells,
the transporter mutant T2 that can be efficiently loaded
with peptide, autologous T cell clones and adherent cells.
Consistent stimulation of a peptide-specific response was
obtained only when either adherent cells or T cell clones were
used as APC. EBV-transformed autologous B cells and to a
higher extent, T2 cells induced a very strong non-peptide-
specific response that obscured a specific response.
Table 1. Phenotypic analysis of adherent cells at different
times of in vitro culture
CD13
CD14
CD4
HLA-ABC
HLA-A2
HLA-DR
HLA-DP
HLA-DQ
CD1a
B7.1
CD54
CD11a
CD3
CD19
Time of
0
20"
126
9
113
52
56
20
9
7
0
19
165
< 1 % c
< 1 %
in vitro culture
2
67
193
14
508
181
545
50
20
11
7
42
217
(h)a
6
143
322
24
550
194
663
156
45
46
27
96
344
24
346
282
9
392
154
151
142
33
38
38
236
264
"Adherent cells from HLA-A2+ donor were analysed for surface
markers at different times of in vitro culture.
bMean fluorescence intensity. The background was subtracted,
cvalues are expressed as percentage because they represent
contaminating cells.
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The population of adherent cells was characterized by
surface staining (Table 1). This population consisted mainly
of CD13+CD14+ monocytes. It should be noted that upon
in vitro culture, monocytes underwent dramatic changes in
surface expression of various markers within the first few
hours of culture (Table 1). The surface expression of HLA-A2
molecules increased at least three times. A similar increase
was evident for total class I as well as class II molecules.
B7.1 was undetectable on freshly isolated monocytes, but
was rapidly up-regulated after in vitro culture. The expression
of ICAM-1 increased five times over 24 h while LFA-1 was
unchanged. These results show that the simple in vitro culture
of fresh monocytes is sufficient to up-regulate MHC, adhesion
and co-stimulatory molecules, thus explaining their efficient
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Fig. 2. Induction of primary in vitro peptide-specific CTL responses by peptide-pulsed activated monocytes. Representative experiments are
shown, in which purified CD8+ T cells from an HLA-A2+ donor were stimulated in replicate cultures with either irradiated (i) PBMC or adherent
monocytes or autologous activated (i) T cell clones pulsed or not with different concentrations of HIV gp120 (121-129 peptide). After 7 days,
cultures were re-stimulated with peptide-pulsed (i) autologous T cell blasts and after a further 7 days the cytotoxic activity of the individual
cultures was measured against 51Cr-labelled target cells pulsed (hatched bars) or not (solid bars) with 10 jig/ml peptide, in the presence or
absence of anti-HLA-A2 or anti-HLA-B27 mAb at an E:T ratio 25:1. On the far right of the figure the number of specific CTL lines above the
total cultures is reported. Similar results were obtained using HBenvAg(335-343). Results represent the percentage mean of specific lysis
expressed by the specific CTL lines.
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presentation of peptide and T cell priming. As previously
reported, human activated T cell clones express high levels
of the same molecules and display 'professional' antigen
presenting capacity (38,39).
Conditions for the generation of primary CTL responses using
peptide-pulsed APC
A general protocol for the generation of specific CTL
responses in vitro was developed. PBMC (4-5X106) were
incubated in 24-well culture plates for 90 min; the non-
adherent cells were removed and the adherent fraction was
extensively washed to deplete contaminating T and B cells
and pulsed with different concentrations of peptide. Due to
the low frequency of peptide-specific T cells in an unprimed
donor, we set up several replicate 2 ml cultures containing
adherent cells and 1.5X106 responding purified (>98%)
CD8+ T cells. Alternatively, responding CD8+ T cells were
cultured with the aforementioned APC (1 x106), that had been
previously pulsed with different concentrations of peptide.
Anyway, after 2 days, IL-2 (50 U/ml) was added and the
cultures were incubated for an additional 5 days before
secondary stimulation with 106 irradiated autologous T cell
blasts that had been pulsed with 10 u,g/ml peptide. After a
further 7 days, the cultures were individually tested for specific
cytotoxicity against homozygous HLA-A2+ EBV-B cells pulsed
or not with peptide.
As evident from a typical experiment reported in Fig. 2,
monocytes pulsed with 100 ng/ml peptide induce a peptide-
specific cytotoxic response detectable in 12 out of 20 replicate
cultures. When autologous activated T cell clones were used
as a source of peptide-pulsed APC a similar cytotoxic
response was obtained (Fig. 2). In contrast, no specific
response was obtained when either peptide-pulsed PBMC
(Fig. 2), T2 cells or EBV-B cells (not shown) were used as
APC. In all cases the responding T cells were peptide specific
and HLA-A2 restricted, as shown by the inhibition of killing
by an anti-HLA-A2 antibody. Similar results were obtained in
10 out of 14 healthy donors tested. Figure 3 clearly shows
that CTL activity was specific for the peptide used in the
priming, since target cells incubated with an HLA-A2.1 binding
control peptide were not lysed.
Further evidence for selective priming of CTL by activated
monocytes was obtained from cytofluorimetric analysis. When
unfractionated HLA-A2+ PBMC were cultured with peptide-
pulsed monocytes a selective expansion of CD8+ T cells was
detected on day 7 (not shown).
Interestingly, we noticed that the optimal timing for peptide
loading on monocytes coincides with the first 4 h of in vitro
culture when there is a maximum increase of surface class I
molecules (Fig. 4 and Table 1).
We conclude that (i) when the only interactions allowed are
those between specific CTL precursor and monocytes or T
cell clones, a CTL response can be readily induced; (ii) in
this case, induction of a primary CTL response triggered by
professional APC does not require CD4+ T cells; and (iii)
failure of total PBMC to mount a CTL response to soluble
peptide cannot be explained by insufficient peptide loading,
but rather by the presence of inappropriate interactions.
M 20
100
24 36 48
E:T rat io
Fig. 3. Dose-response curves of in wf/o-primed CTL. (a)
HIVgp120(121-129J-primed CTL showed cytotoxic activity, at an E:T
ratio 25:1, against '1Cr-labelled target cells, previously pulsed with
increasing concentrations of HIVgp12O(121-129) peptide (O), but
not when pulsed with a non-relevant HLA-A2-binding peptide, as the
HBenvAg(335-343) (A); (b) HIVgp120(121-129)-primed CTL were
compared in their lytic responses against either HIVgp120(121-129)-
sensitized (O) or HBenvAg(335-343)-sensitized (A) target cells at
different E:T ratios.
Co-stimulatory requirements for the induction of a primary
CTL response
The fact that peptide presentation by monocytes or T cell
clones is effective, while presentation by total PBMC (which
include monocytes as well) is not, suggests that total PBMC
contain cells capable of presenting the peptide in a 'sup-
pressing' fashion. To test whether the inability of PBMC to
mount a peptide-specific CTL response was determined by
presentation of peptide on cells that lack co-stimulatory
signals, we asked whether soluble molecules that directly
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Fig. 4. Peptide pulsing of monocytes is most effective in the first hours of in vitro culture. Highly purified CD8+ T cells were primed with
monocytes that were pulsed with gp 120(121-129) peptide for 4 h either immediately after 90 min adherence or after 24 h in vitro culture.
Thereafter, they were re-stimulated and assayed for cytotoxicity against peptide-pulsed (hatched bars) or unpulsed (solid bars) target cells,
as described, at an E:T ratio 25:1. The percentage of the specific CTL lines generated with the two conditions was reported. A CTL line was
defined specific when it expressed a specific lysisof >15%.
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Fig. 5. Co-stimulation by soluble B7.1 and anti-CD28 allows the response of unseparated peptide-pulsed PBMC. Peptide-pulsed unseparated
PBMC, used as a source of APC, were cultured with purified CD8+ T cells in the absence or presence of either chimeric huB7.1-lgM molecules
Of mouse anti-CD28 IgM antibodies. After 7 days, the cells were re-stimulated, as previously described, and after a further 7 days, were tested
in a cytotoxicity assay against peptide-pulsed (hatched bars) or unpulsed (solid bars) target cells, as described, at an E:T ratio 25:1. Results
represent the percentage mean of specific lysis expressed by all the specific CTL lines.
deliver the co-stimulatory signal to T cells might reverse this
effect. When a huB7.1-lgM chimeric protein or an IgM anti-
CD28 mAb was added to unseparated PBMC and peptide,
a clear CTL response was detected (Fig. 5). These results
demonstrate that co-stimulation via CD28 is sufficient for the
induction of the CTL response and suggest that peptide
presentation on frequent non-professional APC present
among PBMC (resting T and B cells expressing class I but
not co-stimulatory molecules) may induce peptide-specific
anergy in CTL precursors.
To further study the co-stimulatory requirements for the
induction of a primary anti-peptide response, we tested the
blocking effect of anti-B7.1 mAb or soluble CTLA-4, that can
bind with high affinity to both B7.1 and B7.2. Interestingly,
neither anti-B7.1 nor soluble CTLA-4 was able to significantly
inhibit the induction of a primary peptide-specific CTL
response by activated monocytes (Fig. 6). Similar results
were obtained using autologous activated T cells as APC (not
shown). Control experiments showed that both anti-B7.1 mAb
and soluble CTLA-4, both added at 5 u.g/ml at the initiation
of culture, significantly blocked the proliferative response
by resting T cells in a primary mixed lymphocyte reaction
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Fig. 6. The induction of a specific CTL response by activated monocytes is not blocked by anti-B7.1 mAb nor by soluble huCTLA-4-hulgG.
Peptide-pulsed monocytes were used as APC to prime a specific CTL response in the presence or absence of different concentrations of
either anti-B7.1 mAb or soluble huCTLA-4-lgG. Results represent the percentage mean of specific lysis expressed by the specific CTL lines
against peptide-pulsed (hatched bars) or unpulsed (solid bars) target cells.
stimulated by either T cell clones or monocytes or dendritic
cells (not shown).
These results suggest that, in addition to B7.1/B7.2 molec-
ules, professional APC may possess additional co-stimulatory
ligands that are sufficient for the induction of a CTL response.
Thus, it appears that each of the two pathways is in itself
sufficient, although not strictly necessary for CTL activation.
Characterization of the responding T cells
To investigate whether the CTL response was due to in vitro
priming of virgin CTL precursors or to the reactivation of
memory cells that had been primed in vivo by the same or
cross-reacting peptides, we compared the response of total
CD8+ T cells with that of CD8+ T cells depleted of CD45RO+
putative memory T cells. As shown in Table 2, the CTL
response was comparable in both populations, indicating that
the contribution to the response of CD45RO+ cells (usually
only 10-20% of total CD8+) is indeed negligible. We cannot
exclude, however, that the responding cells may belong to a
population of resting CD45RA"1" cells that had reverted from
CD45RO+ cells.
CTL obtained by in vitro priming with synthetic peptides
recognize naturally processed peptides on infected cells
We tested whether the primary peptide-specific CD8+ T cells
were able to recognize naturally processed peptides derived
Antigen-specific CTL priming 1749
Table 2. Primary peptide-induced CD8+CD45RCTT cells lyse
peptide-pulsed target cells
Responding population8
Unseparated CD8+ T cells
CD8+CD45RCTT cells
Specific lysis (%)
Peptide-pulsed Unpulsed
targets targets
27
29
0
0
"Unseparated CD8+ T cells or CD45RO depleted-CD8+ T cells
(CD8+CD45RO" T cells), sorted from peripheral blood as described
in Methods, were cultured with peptide-pulsed adherent monocytes
for 7 days followed by re-stimulation with peptide-pulsed autologous
T cell blasts. Afterwards they were tested for their capacity to kill
51Cr-labelled EBV-B cells, pulsed or not with peptide. Percentage of
specific lysis is expressed as mean of triplicate determinations.
from endogenously synthesized proteins. Out of eight
HIVgp120(121-129) peptide-specific CTL lines tested, five
efficiently cross-reacted on HLA-A2+ EBV-B cells infected
with rW expressing HIVgp160 (Fig. 7). Figure 7 also shows
that two representative CD8+ T cell clones, generated from
HIVgp120(121-129) peptide-primed T cells, killed both the
peptide-sensitized A2+ EBV-B cells and the same targets
endogenously expressing HIVgp160. Similarly, CD8+ T cell
clones specific for HBenvAg(335-343) peptide recognized
EBV-B cells infected with rW expressing HBenvAg (not
shown).
Discussion
In the perspective of an adoptive immunotherapy, it is import-
ant to generate in vitro primary CTL responses, i.e. responses
to antigens to which the individual has not been primed
in vivo. We used two nonamer HLA-A2 binding peptides from
HIVgp120 and HBenvAg to define the conditions for the
generation of such CTL responses by CD8+ cells from
seronegative donors. A critical factor appeared to be the mode
of antigen presentation. While peptide pulsing of unseparated
PBMC was invariably ineffective, pulsing of adherent mono-
cytes or activated T cells with peptide induced a peptide-
specific, HLA-A2-restricted CTL response. The responding
CD8+ T cells recognize naturally processed peptides on
target cells infected with rW expressing HIVgp160. This last
is a fundamental requirement in the perspective of adoptive
immunotherapy, in which specific CTL have to recognize
peptides expressed in association with class I molecules on
the surface of host tumor or infected cells, as a product of
endogenous processing. Indeed, the majority of our peptide-
specific CTL lines tested, as well as the CTL clones derived
from them, efficiently killed infected target cells, confirming
previous reports indicating that the immunodominant peptides
always belong to the highest HLA-binding peptides
(10,14,17).
Previous attempts to generate primary in vitro CTL
responses in the mouse system involved the use of either
dendritic cells, which possess high stimulatory capacity (40),
or of the transporter defective mutant RMA-S, which expresses
high levels of empty MHC molecules (12). Recently, human
HD
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Fig. 7. Primary viral peptide-induced CD8+ T cells recognize
naturally processed peptide on infected cells, (a) Purified CD8+ T
cells, derived from healthy donors (HD), were primed with
HIVgp120(121-129)-sensitized adherent monocytes, followed by re-
stimulation with peptide-sensitized autologous T cell blasts. After,
they were tested for their capacity to kill (at an E:T ratio 25:1): 51Cr-
labelled HLA-A2+ EBV-B cells (JY line: HLA-A2.1, B7, C7) infected
with wild-type W (•), or same targets both infected with wild type
W and pulsed with peptide (E3), or same targets infected with rW
expressing HIVgp160 (EZI), or MCr-labelled HLA-A2" EBV-B cells (SA
line: HLA-A24, B7, C7) infected with rW expressing HIVgp160 (•) .
(b) Two representative CD8+ T cell clones (9A11 and 1F4), generated
from gp120(121-129}-primed T cells, were tested for their ability to
kill both HU\-A2+ EBV-B cells sensitized with HIVgp120(121-129)-
peptide (0), and same targets infected with either wild-type W ( • )
or rW expressing HIV gp160 (ED, at an E.T ratio 10:1. Percentage
of specific lysis is expressed as mean of triplicate determinations.
dendritic cells have been demonstrated to be very efficient
APC in priming both naive CD4+ and CD8+ T cells (41,42).
Moreover, the report by Houbiers et al. describes the genera-
tion of primary peptide-specific CTL responses in humans
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after in vitro stimulation with mutant T2 cells (43). This protocol
was not successful in our hands. Indeed, in preliminary
experiments we found that the human transporter defective
mutant T2 cells, although able to bind high peptide levels
(Fig. 1), was not suitable for in vitro priming, because of the
very high level of background activation.
Out of all APC tested, only monocytes and T cell clones
gave reproducible results. The fact that cultured monocytes
are efficient for CTL priming implies that they can bind
sufficient amounts of peptide and present it in the appropriate
co-stimulatory context. This efficient presentation may be
dependent upon the strong up-regulation of MHC class I, as
well as adhesion and co-stimulatory molecules that appear
spontaneously upon in vitro culture within the first 2-6 hours
(Table 1) (44), as shown by the fact that adherent monocytes
are much more effective if pulsed in the first few hours of
culture. The peptide pulsing, done during the up-regulation
of class I molecules by APC, may favour a more efficient
peptide binding to that small percentage of newly synthesized
empty class I molecules, available to bind exogenous
peptides.
We also found that autologous activated T cell clones can
function as APC for CTL priming with antigenic peptides. An
advantage in the use of activated T cells is the lack of a very
low non-specific background of stimulation in the absence of
peptide. We and others have previously demonstrated that
activated T cell clones are indeed professional APC and very
effective in priming other T cells (38,39).
Recently, an alternative approach for inducing primary anti-
tumor CTL in humans was successfully carried out using as
APC non-transformed B cell blasts (45). This together with
the finding that EBV-transformed B cells used as APC were not
able, in our system, to prime antigen-specific CTL responses,
suggests that the two B cell preparations have different APC
capabilities.
It has been previously reported that the density of T cell
epitopes required for the induction of primary CTL response
is much higher than the concentration required for secondary
responses (12). This difference is evident also in the induction
of human CTL, since a 10-fold lower peptide concentration
is required to sensitize target cells for killing.
There are three points that need further discussion. First,
as reported in several experimental systems (12,32,46-49),
our data demonstrate that, when antigen is presented by
professional APC, the requirement for antigen-specific Th
cells in the induction of CTL may not be evident. This result
gives rise to speculation that CTL precursors primed by
professional APC do not require Th cooperation, that is instead
essential when antigen is presented by non-professional APC;
in this last instance, activated T cells themselves, working as
professional APC (39), could simultaneously present peptide
and provide co-stimulation for an appropriate CTL priming.
The second point concerns the pathway of co-stimulation.
Our results demonstrate that direct co-stimulation of
responding CD8+ T cells by soluble ligands via CD28 can
revert the inability of peptide presentation by non-professional
APC. In apparent contrast, however, we found that anti-B7.1
antibody as well as soluble CTLA-4 that blocks both B7.1
and B7.2 (24,25) fail to inhibit induction of a specific CTL
response by activated monocytes. These results suggest
that the B7^CD28 interaction, although by itself sufficient for
priming, is not strictly necessary and that alternative co-
stimulatory pathways may exist. Similar conclusions have
been recently reached by Johnson and Jenkins in an anti-
CD3-dependent T cell activation system (50).
Finally, our data favour the idea that a real CTL priming is
carried out by virgin T cells in our system for two reasons: (i) the
donors were healthy and seronegative and (ii) the depletion of
CD45RO+ cells did not affect the CTL response, indicating
that most of the responding cells belong to the RA+RO~
compartment, even though we cannot exclude that this last
population may contain some CD45RA+ resting T cells that
have reverted from memory CD45RO+ phenotype (51,52).
In conclusion, exploiting the strategies affected by the
immune system for inducing a primary T cell response, we
define a protocol of CTL priming, by using activated mono-
cytes or T cell clones as professional APC, well defined HLA-
binding peptides as immunogenic antigen, and the conditions
favouring productive interactions between specific CTL pre-
cursors and professional APC.
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